Role of centralized review processes for making reimbursement decisions on new health technologies in Europe (Q35454428)

8 August 2017

title

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe (English)

1 reference

8 August 2017

4

Christopher McCabe

1 reference

8 August 2017

Tania Stafinski

1

1 reference

8 August 2017

Devidas Menon

series ordinal

2

1 reference

8 August 2017

Caroline Davis

series ordinal

3

1 reference

8 August 2017

language of work or name

English

0 references

publication date

30 August 2011

1 reference

ClinicoEconomics and Outcomes Research

8 August 2017

published in

1 reference

8 August 2017

volume

3

1 reference

8 August 2017

page(s)

117-186

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

8 August 2017

copyright license

start time

1 August 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Health technology funding decision-making processes around the world: the same, yet different

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Health economics in drug development: efficient research to inform healthcare funding decisions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Pharmaceutical policies in European countries

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Recent developments in pricing and reimbursement of medicines in Ireland

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Pharmacoeconomic evaluation in Ireland: a review of the process

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Access with evidence development in the UK: past experience, current initiatives and future potential.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Access with evidence development schemes: a framework for description and evaluation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Reimbursement agency requirements for health related quality-of-life data: a case study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Real medical benefit assessed by indirect comparison

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Development of health technology assessment in France

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

From idealistic rookies to a regional leader: the history of health technology assessment in Poland

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

History of health technology assessment in Hungary.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

A short history of health technology assessment in Germany.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Austria: history of health technology assessment during the past 20 years

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Role of health technology assessment in shaping the benefits package in The Netherlands

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Procedures and methods of benefit assessments for medicines in Germany.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Health care system in the Czech Republic

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

The last decade of Italian pharmaceutical policy: instability or consolidation?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Methods for determining cost-benefit ratios for pharmaceuticals in Germany

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Definition of the "health benefit basket" in poland

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Health care priority setting: principles, practice and challenges

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

National Authority for Health: France.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Institute for Quality and Efficiency in Health Care: Germany.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

NICE guidance in the Scottish context.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Pharmaceutical pricing and reimbursement reforms in Greece.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

The "health benefit basket" in the Netherlands

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

The Danish health care system: evolution--not revolution--in a decentralized system

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Criteria for determining a basic health services package. Recent developments in The Netherlands.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Pricing and reimbursement of drugs and medical devices in Hungary.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

National Institute for Clinical Excellence and its value judgments

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3202480

Recent developments in pharmacoeconomic evaluation in Ireland

26 September 2018

1 reference

12 December 2020

Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison

1 reference

12 December 2020

Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies

1 reference

12 December 2020

Of problems and solutions. Issues with variable-rate bonds, medical errors led our recent coverage

1 reference

12 December 2020

Reimbursement of medicines in Belgium: role of evidence-based medicine

1 reference

12 December 2020

Value-based medicine pricing: NICE work?

1 reference

12 December 2020

Proposed changes for nurse education in England (UK) as a result of the Darzi report (DoH, 2008a) Health Quality Care for All--NHS next stage review final report: some initial observations.

1 reference

12 December 2020

Deciding subsidy for pharmaceuticals based on ambiguous evidence

1 reference

12 December 2020

Few details on DRG revamp. The CMS may reveal portions of new system in April

1 reference

12 December 2020

Participation in pharmaceutical costs and seniors' access to medicines in the Czech Republic

1 reference

12 December 2020

Challenges in economic evaluation of new drugs: experience with rituximab in Hungary

1 reference

12 December 2020

Health technology assessment: a perspective from Germany

1 reference

12 December 2020

Pricing and reimbursement of pharmaceuticals in Italy

1 reference

12 December 2020

Criteria and procedures for determining benefit packages in health care. A comparative perspective

1 reference

12 December 2020

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines

1 reference

12 December 2020

Identifiers

DOI

10.2147/CEOR.S14407

1 reference

8 August 2017

1 reference

8 August 2017

1 reference